Blueprint Medicines shares are trading lower after SVB Leerink downgraded the stock from Market Perform to Underperform.
Portfolio Pulse from Benzinga Newsdesk
Blueprint Medicines shares are trading lower after SVB Leerink downgraded the stock from Market Perform to Underperform.
June 05, 2023 | 2:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Blueprint Medicines' stock is trading lower after being downgraded by SVB Leerink from Market Perform to Underperform.
The downgrade by SVB Leerink, a well-known investment bank, has a direct impact on Blueprint Medicines' stock price. Investors may lose confidence in the stock due to the downgrade, leading to a decrease in demand and a lower stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100